Indoco Remedies Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
Concerns
- Currently loss-making (EPS ₹-10.7)
- Negative return on equity (ROE -9.4%)
- Low capital efficiency (ROCE 1%)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
INDOCO · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 58.75% | 58.72% | 58.76% | 58.76% | 58.80% | 58.90% |
| FII | 1.69% | 1.92% | 1.48% | 1.70% | 1.25% | 1.24% |
| DII | 19.56% | 19.41% | 18.67% | 18.25% | 18.91% | 18.75% |
| Public | 20.00% | 19.92% | 21.07% | 21.27% | 21.02% | 21.02% |
| Others | — | 0.03% | 0.03% | 0.03% | 0.03% | 0.09% |
Latest News
All newsIndoco Remedies reports Q2FY26 financial results
*Indoco Remedies reports Q2FY26 financial results*. The company has submitted its financial results for the quarter ended September 30, 2026. Results are in-line with market expectations, with no major surprises. Key metrics include revenue of **₹214.5 crore** and net profit of **₹28.3 crore**. 📊 *STOCKS:* INDOCO | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings
Indo Count reports Q1 FY27 financial results
*Indo Count reports Q1 FY27 financial results.* The company has submitted its financial results for the quarter ended June 30, 2026. Results are in-line with market expectations, with no major surprises. Key metrics include revenue of **₹320 crore** and net profit of **₹28 crore**. 📊 *STOCKS:* $INDOCO | 🏢 *SECTOR:* Textiles | #MEDIUMIMPACT #Earnings
Indoco Remedies reports Q1FY26 financial results
*Indoco Remedies reports Q1FY26 financial results*. Indoco Remedies has announced its financial results for the quarter ended June 30, 2026. The outcome includes key performance metrics and financial standings for the first quarter. Further details on revenue, profit, and guidance will be assessed upon full disclosure. 📊 *STOCKS:* INDOCO | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #earnings
Indoco Remedies shares to remain volatile on news publication
*Indoco Remedies shares to remain volatile on news publication* as per a corporate filing disclosing a newspaper publication. The details pertain to regulatory or compliance-related notice, standard for listed entities. No **financial impact** or operational change indicated. Such filings are routine and informational. 📊 *STOCKS:* $INDOCO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #IndocoRemedies
Indoco Remedies allots 14,850 shares under ESOP/ESPS
*Indoco Remedies allots 14,850 shares under ESOP/ESPS* following its board meeting on **27-10-2026**. The allotment pertains to employee stock ownership and purchase schemes. While minor in scale, it reflects ongoing employee incentive initiatives. No immediate financial impact is expected. 📊 *STOCKS:* INDOCO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESOP
Indoco Remedies to host analyst and investor meet
*Indoco Remedies to host an analyst and institutional investor meet.* The company will share updates on business performance and strategy. No financial announcements or major changes were disclosed. The event is part of routine investor engagement. 📊 *STOCKS:* $INDOCO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AnalystMeet
Indoco Remedies shares ESG rating under SEBI norms
*Indoco Remedies shares ESG rating as per SEBI regulations.* This disclosure is part of mandatory listing obligations under **Regulation 30** of SEBI (LODR) 2015. The filing provides no financial impact but confirms compliance with **ESG reporting norms**. Investors may monitor sustainability parameters for long-term positioning. 📊 *STOCKS:* INDOCO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESG
Indoco Remedies holds AGM, shares voting results
*Indoco Remedies holds AGM, shares voting results* — Indoco Remedies Limited has submitted the scrutinizers' report of its Annual General Meeting held on **September 17, 2026**, to the exchange. The company disclosed voting results for all proposed resolutions. No major corporate actions or surprises were reported. Routine corporate disclosure with no immediate market-moving implications. 📊 *STOCKS:* INDOCO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AGM
Indoco Remedies to hold shareholder meeting on Sept 17, 2026
*Indoco Remedies to hold shareholder meeting on Sept 17, 2026.* The event is a routine corporate filing with no disclosed agenda. Such meetings typically address statutory matters or board proposals. No financial impact expected unless major decisions are announced. 📊 *STOCKS:* $INDOCO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholderMeeting
Indoco Remedies' Goa plant inspected by UK MHRA
*Indoco Remedies' Goa plant inspected by UK MHRA.* The UK Medicines and Healthcare products Regulatory Agency (MHRA) conducted an inspection at the company’s Plant I in Goa, manufacturing solid oral dosage forms. The update is part of a regulatory disclosure under SEBI norms. No findings or outcomes are mentioned. 📊 *STOCKS:* INDOCO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulatory
About Indoco Remedies Limited
Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).[1]
HealthcarePharmaceuticals & Biotechnology